β2-Glycoprotein I can exist in 2 conformations: Implications for our understanding of the antiphospholipid syndrome

Blood

Volumn 116, Issue 8, 2010, Pages 1336-1343

  Aǧar, Çetin ^a,b   Van Os, Gwendolyn M A ^a,b   Mörgelin, Matthias ^c   Sprenger, Richard R ^a   Marquart, J Arnoud ^a   Urbanus, Rolf T ^b   Derksen, Ronald H W M ^b   Meijers, Joost C M ^a   De Groot, Philip G ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; EPITOPE; PHOSPHOLIPID ANTIBODY; ANTICOAGULANT AGENT; CARDIOLIPIN;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; CHEMISTRY; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PROTEIN FOLDING; SURFACE PLASMON RESONANCE;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CARDIOLIPINS; HUMANS; PARTIAL THROMBOPLASTIN TIME; PROTEIN CONFORMATION; PROTEIN FOLDING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURFACE PLASMON RESONANCE;

EID: 77956488547     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-12-260976     Document Type: Article

References (38)

1. Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood. 2009;113(5):985-994.
2. Galli M, Comfurius P, Maassen C, et al Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990;335(8705):1544-1547. (Pubitemid 20189625)
3. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87(11):4120-4124. (Pubitemid 120015821)
4. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990;336(8708):177-178.
5. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A. 1991;88(8):3069-3073. (Pubitemid 21916560)
6. Jankowski M, Vreys I, Wittevrongel C, et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood. 2003;101(1):157-162.
7. Pierangeli SS, Colden-Stanfield M, Liu X, et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation. 1999;99(15):1997-2002. (Pubitemid 29183897)
8. Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci U S A. 1984;81(12):3640-3644. (Pubitemid 14087780)
9. Bouma B, de Groot PG, van den Elsen JM, et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J. 1999;18(19):5166-5174.
10. Hunt JE, Simpson RJ, Krilis SA. Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci U S A. 1993;90(6):2141-2145.
11. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A. 1998;95(26):15542-15546.
12. de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic antibeta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood. 2006;107(5):1916-1924.
13. Ioannou Y, Romay-Penabad Z, Pericleous C, et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost. 2009;7(5):833-842.
14. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(10):295-306.
15. Yamaguchi Y, Seta N, Kaburaki J, et al. Excessive exposure to anionic surfaces maintains autoantibody response to beta(2)-glycoprotein I in patients with antiphospholipid syndrome. Blood. 2007;110(13):4312-4318.
16. Kuwana M, Matsuura E, Kobayashi K, et al. Binding of beta 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood. 2005;105(4):1552-1557.
17. Biasiolo A, Rampazzo P, Brocco T, et al. [Antibeta2 glycoprotein I-beta2 glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases. Lupus. 1999;8(2):121-126.
18. Kaburaki J, Kuwana M, Yamamoto M, et al. Disease distribution of beta 2-glycoprotein I-dependent anticardiolipin antibodies in rheumatic diseases. Lupus. 1995;4(suppl 1):S27-S31.
19. Schwarzenbacher R, Zeth K, Diederichs K, et al. Crystal structure of human beta2-glycoprotein: I. Implications for phospholipid binding and the antiphospholipid syndrome. EMBO J. 1999;18(22):6228-6239.
20. Koike T, Ichikawa K, Kasahara H, et al. Epitopes on beta2-GPI recognized by anticardiolipin antibodies. Lupus. 1998;7(suppl 2):S14-S17.
21. Oosting JD, Derksen RH, Entjes HT, Bouma BN, de Groot PG. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost. 1992;67(5):499-502.
22. Engel J, Furthmayr H. Electron microscopy and other physical methods for the characterization of extracellular matrix components: laminin, fibronectin, collagen IV, collagen VI, and proteoglycans. Methods Enzymol. 1987;145:3-78. (Pubitemid 19059239)
23. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009;8(11):998-1005.
24. Kramer G, Sprenger RR, Back J, et al. Identification and quantitation of newly synthesized proteins in Escherichia coli by enrichment of azidohomoalanine-labeled peptides with diagonal chromatography. Mol Cell Proteomics. 2009;8(7):1599-1611.
25. Willems GM, Janssen MP, Pelsers MM, et al. Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. Biochemistry. 1996;35(43):13833-13842.
26. Bozic B, Cucnik S, Kveder T, Rozman B. Avidity of anti-beta-2- glycoprotein I antibodies. Autoimmun Rev. 2005;4(5):303-308.
27. Hammel M, Schwarzenbacher R, Gries A, Kostner GM, Laggner P, Prassl R. Mechanisms of the interaction of beta(2)-glycoprotein I with negatively charged phospholipids membranes. Biochemistry. 2001;40(47):14173-14181.
28. Schousboe I, Rasmussen MS. Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by beta 2-glycoprotein I and anti-beta 2-glycoprotein I. Thromb Haemost. 1995;73(5):798-804.
29. Brighton TA, Hogg PJ, Dai YP, et al. Beta 2-glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant. Br J Haematol. 1996;93(1):185-194.
30. Mori T, Takeya H, Nishioka J, Gabazza EC, Suzuki K. β2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost. 1996;75(1):49-55.
31. Shi T, Iverson GM, Qi JC, et al. β2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I. Proc Natl Acad Sci U S A. 2004;101(11):3939-3944.
32. Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Thromb Haemost. 1999;81(6):929-934.
33. Yasuda S, Tsutsumi A, Chiba H, et al. beta(2)-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis. 2000;152(2):337-346.
34. Gamsjaeger R, Johs A, Gries A, et al. Membrane binding of beta2-glycoprotein I can be described by a two-state reaction model: an atomic force microscopy and surface plasmon resonance study. Biochem J. 2005;389(Pt 3):665-673. (Pubitemid 41117326)
35. Rand JH, Wu XX, Quinn AS, Chen PP, Hathcock JJ, Taatjes DJ. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112(5):1687-1695.
36. van Genderen HO, Kenis H, Hofstra L, Narula J, Reutelingsperger CP. Extracellular annexin A5: functions of phosphatidylserine-binding and two-dimensional crystallization. Biochim Biophys Acta. 2008;1783(6):953-963.
37. de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood. 2007;109(4):1490-1494.
38. Kondo A, Miyamoto T, Yonekawa O, et al. Glycopeptide profiling of beta-2-glycoprotein I by mass spectrometry reveals attenuated sialylation in patients with antiphospholipid syndrome. J Proteomics. 2009;73(1):123-133.